Tarsus Pharmaceuticals Stock Fundamentals
| TARS Stock | USD 33.52 0.10 0.30% |
Tarsus Pharmaceuticals fundamentals help investors to digest information that contributes to Tarsus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tarsus Stock. The fundamental analysis module provides a way to measure Tarsus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tarsus Pharmaceuticals stock.
At this time, Tarsus Pharmaceuticals' Total Other Income Expense Net is comparatively stable compared to the past year. Gross Profit is likely to gain to about 21 M in 2024, despite the fact that Net Loss is likely to grow to (102.2 M). Tarsus | Select Account or Indicator |
Tarsus Pharmaceuticals Company Return On Equity Analysis
Tarsus Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Tarsus Pharmaceuticals Return On Equity | -0.66 |
Most of Tarsus Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tarsus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Tarsus Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Tarsus Pharmaceuticals has a Return On Equity of -0.6607. This is 97.24% lower than that of the Pharmaceuticals sector and 98.19% lower than that of the Health Care industry. The return on equity for all United States stocks is 113.13% higher than that of the company.
Tarsus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tarsus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tarsus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tarsus Pharmaceuticals competition to find correlations between indicators driving Tarsus Pharmaceuticals's intrinsic value. More Info.Tarsus Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Tarsus Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tarsus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tarsus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics of similar companies.Tarsus Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Tarsus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tarsus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tarsus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Tarsus Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (1.36) % | ||||
| Current Valuation | 980.77 M | ||||
| Shares Outstanding | 37.78 M | ||||
| Shares Owned By Insiders | 8.66 % | ||||
| Shares Owned By Institutions | 91.34 % | ||||
| Number Of Shares Shorted | 7.47 M | ||||
| Price To Book | 6.90 X | ||||
| Price To Sales | 77.74 X | ||||
| Revenue | 17.45 M | ||||
| Gross Profit | (17.76 M) | ||||
| EBITDA | (142.28 M) | ||||
| Net Income | (135.89 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 31.73 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 7.29 X | ||||
| Cash Flow From Operations | (117.49 M) | ||||
| Short Ratio | 13.20 X | ||||
| Earnings Per Share | (4.75) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 57.38 | ||||
| Number Of Employees | 244 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 266.22 M | ||||
| Retained Earnings | (244.66 M) | ||||
| Working Capital | 219.19 M | ||||
| Net Asset | 266.22 M |
About Tarsus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 627.3 K | 557.6 K | |
| Total Revenue | 17.4 M | 24.5 M | |
| Cost Of Revenue | 1.6 M | 1.1 M | |
| Stock Based Compensation To Revenue | 1.14 | 1.19 | |
| Sales General And Administrative To Revenue | 1.57 | 0.87 | |
| Research And Ddevelopement To Revenue | 2.88 | 3.03 | |
| Capex To Revenue | (0.32) | (0.30) | |
| Revenue Per Share | 0.59 | 0.56 | |
| Ebit Per Revenue | (8.21) | (7.80) |
Pair Trading with Tarsus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tarsus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tarsus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Tarsus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tarsus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tarsus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tarsus Pharmaceuticals to buy it.
The correlation of Tarsus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tarsus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tarsus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tarsus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.